Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

T C, Eva Minga, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, David Allsup, Francesca Bacchiarri, Sotiria Besikli-Dimou, Sofia Chatzileontiadou, Rosa Collado, Zadie Davis, Maria Dimou, David Donaldson, Maria Efstathopoulou, Sara Galimberti, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Eleftheria Hatzimichael, Jose-Angel Hernandez-Rivas, Gloria Iacoboni, Iliana Konstantinou, Ioannis Kotsianidis, Jana Kotaskova, Andreas Epameinondas Koumpis, Zuzana Kubova, Jorge Labrador, Luca Laurenti, Juan Marquet, Stanislava Maslejova, Carlota Mayor-Bastida, Fatima Miras, Riccardo Moia, Almudena Navarro-Bailon, Jacopo Olivieri, Maria Papaioannou, Anna Puiggros, Gian Matteo Rigolin, Mattia Schipani, Tereza Shokralla, Martin Simkovic, Antigoni Tranidou, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Renata Walewska, Lucrecia Yanez San Segundo, Jana Zuchnicka, David Graham Oscier, Alessandro Gozzetti, Panayiotis Panayiotidis, Francesc Bosch, Paolo Sportoletti, Blanca Espinet, Gerassimos Pangalis, Maria Angelopoulou, Tomas Papajik, Roberta Murru, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Niki Stavrogianni, Livio Trentin, Lukas Smolej, Mark Caterwood, Martin Spacek, Sarka Pospisilova, Michael Doubek, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2024) 144 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2024-202046

Published: 2024

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Blood (2024) 144 (Supplement 1): 242.

https://doi.org/10.1182/blood-2024-200528

Published: 2024

Journal Articles

Ibrutinib in CLL: benefit for all?

Antonio Cuneo, Paolo Ghia

Blood (2024) 143 (16): 1558–1559.

https://doi.org/10.1182/blood.2023023758

Published: 2024

Journal Articles

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Blood (2023) 142 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2023-181553

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2023-180036

Published: 2023

Journal Articles

COVID-19 prophylaxis: half-full or half-empty glass?

Lydia Scarfò, Antonio Cuneo

Blood (2023) 141 (2): 130–132.

https://doi.org/10.1182/blood.2022018858

Published: 2023

Journal Articles

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Juan Gonzalo Correa, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Shaimaa El-Ashwah, Alicia Enrico, Blanca Espinet, Lucia Farina, Angela Ferrari, Myriam Foglietta, Alberto Lopez-Garcia, Jose A. Garcia-Marco, Rocío García-Serra, Massimo Gentile, Eva Gimeno, Maria Gomes da Silva, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, José Ángel Hernández-Rivas, Tobias Herold, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Оlga B. Kalashnikova, Elżbieta Kalicińska, Arnon P. Kater, Sabina Kersting, Maya Koren-Michowitz, Jorge Labrador Gomez, Deepesh Lad, Luca Laurenti, Alberto Fresa, Mark-David Levin, Carlota Mayor Bastida, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet, Biljana Mihaljevic, Ivana Milosevic, Fatima Mirás, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Raquel Nunes, Jacopo Olivieri, Miguel Arturo Pavlovsky, Inga S. Piskunova, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Gianluigi Reda, Gian Matteo Rigolin, Amit Shrestha, Martin Šimkovič, Svetlana Smirnova, Martin Špaček, Paolo Sportoletti, Oana Stanca, Niki Stavroyianni, Doreen Te Raa, Kristina Tomic, Sanne Tonino, Livio Trentin, Ellen Van Der Spek, Michel van Gelder, Marzia Varettoni, Andrea Visentin, Candida Vitale, Vojin Vukovic, Ewa Wasik-Szczepanek, Tomasz Wróbel, Lucrecia Yanez San Segundo, Mohamed A Yassin, Marta Coscia, Alessandro Rambaldi, Emili Montserrat, Robin Foà, Antonio Cuneo, Marc Carrier, Paolo Ghia, Kostas Stamatopoulos

Blood (2022) 140 (Supplement 1): 2772–2775.

https://doi.org/10.1182/blood-2022-169909

Published: 2022

Journal Articles

Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML

Matteo Marchesini, Andrea Gherli, Elisa Simoncini, Anna Montanaro, Natthakan Thongon, Luca Pagliaro, Federica Vento, Lucas Moron Dalla Tor, Chiara Liverani, Raffaella Zamponi, Elena Follini, Benedetta Cambò, Bruno Lorusso, Roberta La Starza, Antonio Cuneo, Cristina Mecucci, Simona Colla, Federico Quaini, Giovanni Roti

Blood (2022) 140 (Supplement 1): 673–674.

https://doi.org/10.1182/blood-2022-158990

Published: 2022

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Blood (2022) 140 (Supplement 1): 7045–7046.

https://doi.org/10.1182/blood-2022-159334

Published: 2022

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

Stefano Molica, Luca Laurenti, Paolo Ghia, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Francesca Mauro, Anna Maria Frustaci, Daniele Vallisa, Fabrizio Pane, Giuliana Gualberti, Emilia Iannella, Paola Finsinger, Morena Caira, Paolo Sportoletti

Blood (2021) 138 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2021-148308

Published: 2021

Journal Articles

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 138 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2021-148738

Published: 2021

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

NARROW

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Ibrutinib in CLL: benefit for all?

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

COVID-19 prophylaxis: half-full or half-empty glass?

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only